ReviewHNO2026
[Role of human papillomavirus vaccination in prevention of oropharyngeal cancer and recommendations for patients and relatives].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing worldwide, particularly among younger men without classical risk factors. High-risk HPV types are the primary cause. Prophylactic vaccines offer the first effective means of primary prevention, with efficacy demonstrated primarily through the reduction in oropharyngeal HPV infections.
objectiveThis article aims to present the current evidence on HPV vaccination for prevention of OPSCC, including vaccination coverage, guideline recommendations, and implications for patients and their close contacts. MATERIALS AND
methodsA systematic literature search was performed in PubMed (2000-2025) on HPV vaccination and oropharyngeal cancer, including systematic reviews, meta-analyses, and cohort and randomized studies as well as national and international guidelines.
resultsHuman papillomavirus vaccination reduces the prevalence of oropharyngeal high-risk HPV infections by 80-90% and significantly lowers the risk of persistent infections. Relatives and sexual partners of OPSCC patients have a mildly increased risk of HPV-associated malignancies. Vaccination coverage in Germany is particularly low among boys; therapeutic HPV vaccines are currently being investigated in clinical trials. Modeling studies indicate that substantial reductions in the OPSCC incidence can only be achieved with significantly higher vaccination rates than those currently seen in Germany.
conclusionHuman papillomavirus vaccination is an effective tool for primary prevention of oropharyngeal infections and, indirectly, OPSCC. Sustainable impact requires gender-neutral and easily accessible vaccination programs, targeted inclusion of close contacts, and further research into therapeutic vaccination strategies.
Indexed as
Identifiers
41565797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.